ProfoundBio announced that management will be participating in one-on-one meetings with investors at the 2023 RBC Capital Markets Healthcare Private Company Conference, being held virtually December 13-14, 2023.
| SEATTLE, Dec. 5, 2023 /PRNewswire/ --ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one meetings with investors at the 2023 RBC Capital Markets Healthcare Private Company Conference, being held virtually December 13-14, 2023. Executives will participate in a fireside chat at the conference on December 13 at 3:10pm EST. In addition, ProfoundBio management will be participating in one-on-one meetings with investors at the 42nd Annual J.P. Morgan Healthcare Conference, taking place from January 8-11, 2024 in San Francisco, CA.
About ProfoundBio ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages. The company’s clinical stage programs are rinatabart sesutecan (Rina-S; PRO1184), an ADC targeting folate receptor alpha, PRO1160, an ADC targeting CD70, and PRO1107, an ADC targeting PTK7. ProfoundBio is headquartered in Seattle, WA, USA. For more information, please visit www.profoundbio.com.
SOURCE ProfoundBio |
View original content to download multimedia:
